Catherine Diefenbach, MD, an American Society of Hematology expert and director of the Clinical Lymphoma Program at NYU Langone's Perlmutter Cancer Center, discussed the evolving state of diffuse ...

Ahead of the upcoming American Society of Hematology annual meeting, a multicenter study published in the Journal of Clinical ...

Matthew S. McKinney, MD, reflects on his first experience of treating a patient with diffuse large B-cell lymphoma (DLBCL) as a new attending at Duke University. The patient, a woman with multiple ...

Treatment with R-GemOx was associated with significant health care resource utilization, high costs surrounding treatment, and low overall survival in elderly patients with diffuse large B-cell ...

Suchitra Sundaram, MD, emphasizes the significant disparities in the treatment and outcomes of patients with diffuse large B-cell lymphoma (DLBCL), which arise from a complex interaction of factors ...

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or ...

BOSTON--(BUSINESS WIRE)--Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel ...

What we expect to see for aggressive lymphoma at the American Society of Hematology meeting in December is probably ...

Shares of ADC Therapeutics fell after it reported the death of two patients in a late-stage trial for treating an aggressive cancer that starts in white blood cells. The stock fell 7.6% to $4.25 in ...

Zynlonta and glofitamab show high response and durable remission rates in early r/r DLBCL trial data from ADC Therapeutics, ...